Abstract
BackgroundOnly ~20% of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) patients respond to immune-checkpoint blockade (ICB) therapy. A major roadblock is the immunosuppressive nature of the tumor...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
